



PQRI/USP Workshop on Elemental Impurity Requirements in a Global Environment – Next Steps?

March 31 – April 1, 2015
USP Meeting Center
Rockville, Maryland

Workshop Description

The time to finalize implementation plans is now! This workshop will provide practical solutions to challenges involved in global implementation of the Elemental Impurity (EI) guidelines and standards. Specific topics will include the following:

- Assessment of Ingredients – Excipients & APIs
- Analytical Testing Considerations
- Successful Risk Assessment Methodologies
- Finished Dosage Form Considerations
- Implementation Strategy

This workshop will include global experts from industry, regulatory authorities, pharmacopeias, and academia who are intimately involved in this area.

Workshop Planning Committee

David R. Schoneker, Chair, Colorcon, IPEC Americas, and PQRI

William Dale Carter, JM Huber

David J. Fillar, Perrigo Co.

John F. Kauffman, Ph.D., US Food and Drug Administration

Andrew Teasdale, Ph.D., Astra Zeneca

Katherine L. Ulman, Dow Corning and IPEC-Americas

Phyllis Walsh, Merck

Kakhashan Zaidi, Ph.D., US Pharmacopeia

Priscilla S. Zawislak, Ashland Inc.

Preliminary Program Agenda

MARCH 31, 2015

8:00 am – 8:15 am

Registration Check In

8:15 am *Amphitheater*

Welcome and Introductory Remarks

David R. Schoneker

Colorcon, IPEC-Americas,
PQRI Steering Committee, and
EI Coalition

8:30 am

**Session I: Assessment of Ingredients –
Excipients and APIs**

FDA Expectations for Archiving Data
in the Quality System

FDA Speaker TBD

Expectations for APIs and Excipients in the EU

EDQM Speaker TBD

9:30 am

Coffee Break

9:45 am

**Session II: Elemental Impurity
Measurement and Assessment**

Methods/Validation

Nancy Lewen

Bristol Myers Squibb Company,
USP EI Expert Panel and Chemical Analysis Expert
Committee

Analytical Challenges/Round Robin Study

Donna S. Seibert, Ph.D.

Perrigo
EI Coalition

Industry Analytical Data Collected by Global
Groups/FDA-IPEC Excipient Study Data

Andrew Teasdale, Ph.D.

Astra Zeneca
JPAG EI Committee

11:00 am

Lunch

12:00 pm

Breakout Sessions – there will be four concurrent rooms
utilized to discuss the topic to facilitate small group
discussion

Breakout Session I

Topic: Assessment of Ingredients –
Excipients and APIs

Facilitators: K. Ulman, D. Carter, D. Schoneker,
P. Zawislak, and N. Schwarzwaldner

Discussion Points to include:

- Variability of Natural & Mined
Ingredients – Excursions
- Lack of Predictability for Risk Assessment
- Acid Leach vs. Total Dissolution – Data
Interpretation
- Appropriate Supplier-User Communication
- How to Assess What is “Likely to be Present”? –
30% Rule
- Data Sharing – Development of an
Excipient Elemental Impurity Database

1:15 pm

Breakout Session II

Topic: Analytical Testing Considerations

Facilitators: D. Seibert, T. Shelbourn, A. Teasdale and
K. Ulman

Discussion Points to include:

- Best Practices
- Method Validation
- Dosage Form Considerations
- Acid Leach vs. Total Dissolution - Sample Prep
- Inter-Laboratory Reproducibility – Coalition Collaborative Study Results
- Instrument Issues – Precision, Accuracy, and Corrections
- Matrix Interferences
- Potential Solutions

2:30 pm

Coffee Break

2:45 pm *Amphitheater*

Session III: Elemental Impurity Control Strategies for Finished Drug Products

Successful Risk Assessment Methodologies

EMA Speaker TBD

General Approaches to Elemental Impurity Product Assessments

Mark G. Schweitzer, Ph.D.

Novartis

ICH Q3D EWG

Finished Dosage Form Considerations

Finished Dosage Form Testing

Wilfried Keurentjes

Merck

Applying Q3D to Other Routes of Administration

John K. Leighton, Ph.D., *Invited*

US Food and Drug Administration

ICH Q3D Expert Working Group

How to Deal with Other Routes of Administration in the EU

Roland Frötschl, Ph.D.

BfArM

USP EI Expert Panel

4:55 pm

Closing Remarks

David R. Schoneker

Colorcon

PQRI Steering Committee

EI Coalition

5:30 pm – 7:30 pm

Reception

please note location is offsite and adjacent to the Twinbrook Metro Station

Held at the Hilton Hotel and Executive Meeting Center

1750 Rockville Pike

Rockville, Maryland 20852

APRIL 1, 2015

8:00 am

Registration

8:30 am *Amphitheater*

Summary of Day 1, Goals for Day 2

David R. Schoneker

Colorcon

PQRI Steering Committee

EI Coalition

8:45 am

Breakout Session III

Topic: Successful Risk Assessment Methodologies

Facilitators: D. Fillar, P. Walsh, D. Carter, N. Lewen

Discussion Points to include:

- Key Considerations and Tools
- Predictability
- When is Testing Needed and When is it Not?
- Case Studies to Demonstrate Appropriate Control Strategies

10:15 am
Coffee Break

10:30 am
Breakout Session IV

Topic: Finished Dosage Form Considerations
Facilitators: P. Walsh, A. Teasdale, D. Fillar, N. Schwarzwaldner, T. Shelbourn, J. Poulos

Discussion Points to include:

- Finished dosage Form Testing Protocols – What is the Industry Doing?
- Oral, Parenteral, and Inhalation Issues
- How to Deal with Other Routes of Administration with Less Defined Dosing/Exposure (Topicals, etc.)
- Are Reformulations Needed for Some Drug Products or Should Exemptions be Granted?
- How to Apply for an Exemption in Different Regions

12:00 pm
Lunch

1:00 pm Amphitheater
Session IV: Implementation Strategy

ICH Training Plans-Implementation Working Group (IWG)

John F. Kauffman, Ph.D.
US Food and Drug Administration
ICH Q3D EWG

Regional and Global Roll-out by Regulatory Authorities –Timing and Compliance
MHLW/JP Speaker TBD

Harmonization of Requirements Between ICH Q3D and Pharmacopeias

Kakhashan Zaidi, Ph.D.
US Pharmacopeia

Coordination with Requirements in Other Countries (i.e., China, India, Brazil, Taipei, South Korea, etc.)

Industry Speaker TBD

Regulatory Expectations at Time of Registration and During Ongoing GMP Inspections

Danae Christodoulou, Invited
US Food and Drug Administration
EI Implementation Working Group

3:30 pm
Breakout Summary Reports

Breakout Session I: Katherine Ulman, Dow Corning and IPEC-Americas

Breakout Session II: Donna Seibert, Perrigo Co.

Breakout Session III: David J. Fillar, Perrigo Co

Breakout Session IV: Phyllis Walsh, Merck

4:30 pm
Summary of Feedback and Action Plans

David R. Schoneker
Colorcon, IPEC-Americas
PQRI Steering Committee, and
EI Coalition

PQRI Mission Statement

The Product Quality Research Institute (PQRI) is a non-profit consortium of organizations working together to generate and share timely, relevant, and impactful information that advances drug product quality and development. By virtue of its diverse membership, PQRI provides a unique forum to focus critical thinking, conduct research, exchange information, and propose methodology or guidance to pharmaceutical companies, regulators, and standard setting organizations.

PQRI Member Organizations

AAPS

American Association of Pharmaceutical Scientists

CHPA

Consumer Healthcare Products Association

FDA/CDER

U.S. Food and Drug Administration, Center for Drug Evaluation and Research

HC

Health Canada

IPEC-Americas

International Pharmaceutical Excipients Council of the Americas

ISPE

International Society of Pharmaceutical Engineers

PDA

Parenteral Drug Association

USP

United States Pharmacopeia

Board of Directors

Anthony DeStefano, Ph.D., **Chair**

Louis Yu, Ph.D., **Treasurer**

Kevin Hool, Ph.D.

Margaret Szymczak, Ph.D.

Vinod Shah, Ph.D.

PQRI Steering Committee

Margaret Szymczak, Ph.D., **Chair**

Kevin Hool, Ph.D., **Vice Chair**

AAPS

Lynn Van Campen, Ph.D.

CHPA

John Punzi, Ph.D.

FDA

Lawrence Yu, Ph.D.

HC

Anita DiFranco

IPEC-Americas

Dave R. Schoneker

ISPE

Joe Famulare

PDA

Rich Levy, Ph.D.

USP

Kevin Hool, Ph.D.



Venue and Registration

The workshop is being held at the USP Meeting Center in Rockville, Maryland.

Hotel reservations can be made online at

https://secure3.hilton.com/en_US/hi/reservation/book.htm?ctyhocn=IADMRHF&corporateCode=N2694865 using the PQRI corporate discount.

The link allows you to take advantage of that discount when you enter your reservation information. Please note that space is limited so do not delay, make your reservations today!

Registration for the conference can be made by going to the SignMeUp website at www.signmeup.com/104624.

For additional information and/or assistance, please contact Vicki Penn at pennv@pqri.org.